Cargando…

Targeting the Mutational Landscape of Bystander Cells: Drug-Promoted Blood Cancer From High-Prevalence Pre-neoplasias in Patients on BRAF Inhibitors

Drug-promoted cancers are increasingly recognized as a serious clinical problem in patients receiving BRAF inhibitory treatment. Here we report on a patient with BRAF mutant hairy cell leukemia and monoclonal B-cell lymphocytosis (MBL), who responded durably to BRAF/MEK inhibitors (BRAFi/MEKi) but e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simnica, Donjete, Ittrich, Harald, Bockemeyer, Carsten, Stein, Alexander, Binder, Mascha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517330/ https://www.ncbi.nlm.nih.gov/pubmed/33042833 http://dx.doi.org/10.3389/fonc.2020.540030

Ejemplares similares

PD-L1 Amino Acid Position 88 Represents a Hotspot for PD-L1 Stability With Relevance for PD-L1 Inhibition
por: Claaß, Luise Victoria, et al.
Publicado: (2022)

Maturation trajectories and transcriptional landscape of plasmablasts and autoreactive B cells in COVID-19
por: Schultheiß, Christoph, et al.
Publicado: (2021)

Subclonal heterogeneity sheds light on the transformation trajectory in IGLV3-21(R110) chronic lymphocytic leukemia
por: Paschold, Lisa, et al.
Publicado: (2022)

Landscape of T‐cell repertoires with public COVID‐19‐associated T‐cell receptors in pre‐pandemic risk cohorts
por: Simnica, Donjete, et al.
Publicado: (2021)

Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients
por: Grimm, Juliane, et al.
Publicado: (2022)

B cells in autoimmune hepatitis: bystanders or central players?
por: Schultheiß, Christoph, et al.
Publicado: (2022)

Translational analysis and final efficacy of the AVETUX trial – Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
por: Tintelnot, Joseph, et al.
Publicado: (2022)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Rapid Hypermutation B Cell Trajectory Recruits Previously Primed B Cells Upon Third SARS-Cov-2 mRNA Vaccination
por: Paschold, Lisa, et al.
Publicado: (2022)

High-Throughput Immunogenetics Reveals a Lack of Physiological T Cell Clusters in Patients With Autoimmune Cytopenias
por: Simnica, Donjete, et al.
Publicado: (2019)

A Rare Finding of a BRAF Mutation in Renal Cell Carcinoma with Response to BRAF-Directed Targeted Therapy
por: Banerjee, Natasha, et al.
Publicado: (2016)

Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide
por: Mährle, Thorben, et al.
Publicado: (2019)

KRAS and BRAF somatic mutations in colonic polyps and the risk of metachronous neoplasia
por: Juárez, Miriam, et al.
Publicado: (2017)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

Clinicopathologic Features and Prognosis of BRAF Mutated Colorectal Cancer Patients
por: Guan, Wen-Long, et al.
Publicado: (2020)

Exploration of the Proteomic Landscape of Small Extracellular Vesicles in Serum as Biomarkers for Early Detection of Colorectal Neoplasia
por: Chang, Li-Chun, et al.
Publicado: (2021)

SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2
por: von Wenserski, Lisa, et al.
Publicado: (2020)

Case report: Clinical success targeting BRAF-mutated, hormone receptor positive, HER2- negative advanced breast cancer patient with BRAF-inhibitor plus MEK- inhibitor
por: López de Sá, Alfonso, et al.
Publicado: (2022)

What is the Role of the Bystander Response in Radionuclide Therapies?
por: Brady, Darren, et al.
Publicado: (2013)

Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients
por: Rosati, Gerardo, et al.
Publicado: (2021)

Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease
por: Schultheiß, Christoph, et al.
Publicado: (2020)

Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives
por: Ottaiano, Alessandro, et al.
Publicado: (2022)

Enhancing the Bystander and Abscopal Effects to Improve Radiotherapy Outcomes
por: Farias, Virgínea de Araújo, et al.
Publicado: (2020)

Radiation-induced bystander effect and its clinical implications
por: Tang, Haoyi, et al.
Publicado: (2023)

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination
por: Ellingsen, Espen Basmo, et al.
Publicado: (2022)

Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation
por: Liu, Chaoyuan, et al.
Publicado: (2022)

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
por: Sweetlove, Melanie, et al.
Publicado: (2015)

Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations
por: Heinzerling, L, et al.
Publicado: (2013)

Prediction of BRAF mutation status in glioblastoma multiforme by preoperative ring enhancement appearances on MRI
por: Cai, Xiaomin, et al.
Publicado: (2022)

Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective
por: Salman, Pamela, et al.
Publicado: (2023)

Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review
por: Puri, Megha, et al.
Publicado: (2023)

Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling
por: Tintelnot, Joseph, et al.
Publicado: (2020)

Bystander communication and cell cycle decisions after DNA damage
por: Jaiswal, Himjyot, et al.
Publicado: (2015)

Safety and Tolerability of BRAF Inhibitor and BRAF Inhibitor-Based Combination Therapy in Chinese Patients With Advanced Melanoma: A Real World Study
por: Liu, Xing, et al.
Publicado: (2021)

BRAF Inhibitor Resistance Confers Increased Sensitivity to Mitotic Inhibitors
por: Misek, Sean A., et al.
Publicado: (2022)

Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
por: Jain, Tania, et al.
Publicado: (2015)

KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study
por: Negru, Serban, et al.
Publicado: (2014)

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers
por: Yang, Qiwei, et al.
Publicado: (2018)

BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective
por: Yan, Ningning, et al.
Publicado: (2022)

The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape
por: Vanni, Irene, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h4hduphq898chds2nq8bnvtmte